CMS’s Proposed Prescription Drug Value-Based Purchasing Rule

Paving the Way for Payment Innovation On June 17, 2020, CMS announced a proposed rule that would change how pharmaceutical manufacturers report pricing and discounts to Medicaid.  The goal of this new rule is to reduce regulatory requirements that currently hinder manufacturers’ ability to enter into value-based agreements and other innovative payment models. From our perspective, […]

CMS’s Proposed Prescription Drug Value-Based Purchasing Rule Read More »